Grant: Project Grant
University of Alberta
$818,550.00
An Immuno-PET-PDGFRa Conjugate to Identify Metastases and Predict Outcomes for Papillary Thyroid Cancer
EF 2019-20
Résumé
We have identified a marker of aggressive disease in papillary thyroid cancer that can be used as a means to finding metastatic disease. Metastatic disease is common but often hard to find in thyroid cancer patients. We have created an imaging tool that can not only find where metastases are using a PET scan, but also can determine if the disease is sensitive to radioactive iodine. This new imaging scan can be used to map out a treatment plan that avoids high doses of unnecessary, or ineffective, radioactive iodine therapy in a cancer that affects more than 7000 patients a year in Canada. In addition, we are mapping the process of cell fate to identify pathways that drive metastases as potential new targets for future therapy.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
408598
Name
McMullen Todd
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
An Immuno-PET-PDGFRa Conjugate to Identify Metastases and Predict Outcomes for Papillary Thyroid Cancer
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$818,550
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cell Fate; Dedifferentiation; Papillary Thyroid Cancer; Positron Emission Tomography; Radiopharmaceutical
Abstract
We have identified a marker of aggressive disease in papillary thyroid cancer that can be used as a means to finding metastatic disease. Metastatic disease is common but often hard to find in thyroid cancer patients. We have created an imaging tool that can not only find where metastases are using a PET scan, but also can determine if the disease is sensitive to radioactive iodine. This new imaging scan can be used to map out a treatment plan that avoids high doses of unnecessary, or ineffective, radioactive iodine therapy in a cancer that affects more than 7000 patients a year in Canada. In addition, we are mapping the process of cell fate to identify pathways that drive metastases as potential new targets for future therapy.
Competitiondate
201909
Approvedterm2
5 yrs 0 mth
Pinamesdelim
McMullen, Todd
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $818,550~ $0~
